Literature DB >> 28096392

Continual renewal and replication of persistent Leishmania major parasites in concomitantly immune hosts.

Michael A Mandell1, Stephen M Beverley2.   

Abstract

In most natural infections or after recovery, small numbers of Leishmania parasites remain indefinitely in the host. Persistent parasites play a vital role in protective immunity against disease pathology upon reinfection through the process of concomitant immunity, as well as in transmission and reactivation, yet are poorly understood. A key question is whether persistent parasites undergo replication, and we devised several approaches to probe the small numbers in persistent infections. We find two populations of persistent Leishmania major: one rapidly replicating, similar to parasites in acute infections, and another showing little evidence of replication. Persistent Leishmania were not found in "safe" immunoprivileged cell types, instead residing in macrophages and DCs, ∼60% of which expressed inducible nitric oxide synthase (iNOS). Remarkably, parasites within iNOS+ cells showed normal morphology and genome integrity and labeled comparably with BrdU to parasites within iNOS- cells, suggesting that these parasites may be unexpectedly resistant to NO. Nonetheless, because persistent parasite numbers remain roughly constant over time, their replication implies that ongoing destruction likewise occurs. Similar results were obtained with the attenuated lpg2- mutant, a convenient model that rapidly enters a persistent state without inducing pathology due to loss of the Golgi GDP mannose transporter. These data shed light on Leishmania persistence and concomitant immunity, suggesting a model wherein a parasite reservoir repopulates itself indefinitely, whereas some progeny are terminated in antigen-presenting cells, thereby stimulating immunity. This model may be relevant to understanding immunity to other persistent pathogen infections.

Entities:  

Keywords:  latency; quiescence; stem cell-like; trypanosomatid protozoan parasite; vaccination

Mesh:

Year:  2017        PMID: 28096392      PMCID: PMC5293024          DOI: 10.1073/pnas.1619265114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  73 in total

1.  The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects.

Authors:  M H Tattersall; B Brown; E Frei
Journal:  Nature       Date:  1975-01-17       Impact factor: 49.962

2.  Photoconvertible pathogen labeling reveals nitric oxide control of Leishmania major infection in vivo via dampening of parasite metabolism.

Authors:  Andreas J Müller; Salome Aeschlimann; Romain Olekhnovitch; Mariko Dacher; Gerald F Späth; Philippe Bousso
Journal:  Cell Host Microbe       Date:  2013-10-16       Impact factor: 21.023

Review 3.  The fate and persistence of Leishmania major in mice of different genetic backgrounds: an example of exploitation of the immune system by intracellular parasites.

Authors:  P Launois; J A Louis; G Milon
Journal:  Parasitology       Date:  1997       Impact factor: 3.234

4.  Presentation of the Leishmania antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites.

Authors:  N Courret; E Prina; E Mougneau; E M Saraiva; D L Sacks; N Glaichenhaus; J C Antoine
Journal:  Eur J Immunol       Date:  1999-03       Impact factor: 5.532

5.  A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation.

Authors:  G F Späth; S M Beverley
Journal:  Exp Parasitol       Date:  2001-10       Impact factor: 2.011

Review 6.  Leishmaniasis: complexity at the host-pathogen interface.

Authors:  Paul Kaye; Phillip Scott
Journal:  Nat Rev Microbiol       Date:  2011-07-11       Impact factor: 60.633

7.  Recurrent cutaneous leishmaniasis: a role for persistent parasites?

Authors:  T Aebischer
Journal:  Parasitol Today       Date:  1994-01

8.  Platelet activation attracts a subpopulation of effector monocytes to sites of Leishmania major infection.

Authors:  Ricardo Goncalves; Xia Zhang; Heather Cohen; Alain Debrabant; David M Mosser
Journal:  J Exp Med       Date:  2011-05-23       Impact factor: 14.307

Review 9.  The early interaction of Leishmania with macrophages and dendritic cells and its influence on the host immune response.

Authors:  Dong Liu; Jude E Uzonna
Journal:  Front Cell Infect Microbiol       Date:  2012-06-12       Impact factor: 5.293

10.  iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice.

Authors:  Carl De Trez; Stefan Magez; Shizuo Akira; Bernhard Ryffel; Yves Carlier; Eric Muraille
Journal:  PLoS Pathog       Date:  2009-06-26       Impact factor: 6.823

View more
  38 in total

1.  Farnesyl pyrophosphate synthase is essential for the promastigote and amastigote stages in Leishmania major.

Authors:  Sumit Mukherjee; Somrita Basu; Kai Zhang
Journal:  Mol Biochem Parasitol       Date:  2019-03-26       Impact factor: 1.759

2.  Case Reports: Late Emergence of Cutaneous Leishmaniasis in an Immunocompromised Patient in a Non-Endemic Setting.

Authors:  David New; Benjamin A Rogers
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

3.  Secondary Prophylaxis with Liposomal Amphotericin B in a Patient with Mucosal Leishmaniasis Undergoing Immunobiological Therapy for Active Ankylosing Spondylitis.

Authors:  Antonio Carlos Nicodemo; Heitor Franco de Andrade; Pablo Muñoz Torres; Valdir Sabbaga Amato
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

4.  Macromolecular biosynthetic parameters and metabolic profile in different life stages of Leishmania braziliensis: Amastigotes as a functionally less active stage.

Authors:  Marlene Jara; Maya Berg; Guy Caljon; Geraldine de Muylder; Bart Cuypers; Denis Castillo; Ilse Maes; María Del Carmen Orozco; Manu Vanaerschot; Jean-Claude Dujardin; Jorge Arevalo
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

5.  Modulation of Aneuploidy in Leishmania donovani during Adaptation to Different In Vitro and In Vivo Environments and Its Impact on Gene Expression.

Authors:  F Dumetz; H Imamura; M Sanders; V Seblova; J Myskova; P Pescher; M Vanaerschot; C J Meehan; B Cuypers; G De Muylder; G F Späth; G Bussotti; J R Vermeesch; M Berriman; J A Cotton; P Volf; J C Dujardin; M A Domagalska
Journal:  MBio       Date:  2017-05-23       Impact factor: 7.867

Review 6.  Protozoan persister-like cells and drug treatment failure.

Authors:  Michael P Barrett; Dennis E Kyle; L David Sibley; Joshua B Radke; Rick L Tarleton
Journal:  Nat Rev Microbiol       Date:  2019-08-23       Impact factor: 60.633

Review 7.  Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis - challenges and opportunities.

Authors:  Katrien Van Bocxlaer; Simon L Croft
Journal:  RSC Med Chem       Date:  2021-01-07

8.  Diversity and Within-Host Evolution of Leishmania donovani from Visceral Leishmaniasis Patients with and without HIV Coinfection in Northern Ethiopia.

Authors:  Susanne U Franssen; Yegnasew Takele; Emebet Adem; Mandy J Sanders; Ingrid Müller; Pascale Kropf; James A Cotton
Journal:  mBio       Date:  2021-06-29       Impact factor: 7.867

Review 9.  Balancing de novo synthesis and salvage of lipids by Leishmania amastigotes.

Authors:  Kai Zhang
Journal:  Curr Opin Microbiol       Date:  2021-07-23       Impact factor: 7.584

Review 10.  Long-Lived Skin-Resident Memory T Cells Contribute to Concomitant Immunity in Cutaneous Leishmaniasis.

Authors:  Phillip Scott
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-10-01       Impact factor: 9.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.